Abbott Laboratories

ABT

Healthcare Medical Devices

Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.

Revenue
+14.5%
EPS
−43.6%
Free cash flow
−46.6%
Total debt
+140.8%

Quarter to September 2026, against a year earlier

107.41 1.11 −1.02%
Market cap
$186.1B
P/E
40.1×
Fwd P/E FY26e
35.9×
Dividend yield
2.35%
F-score
5/9
ROIC
5.29%
Net debt / EBITDA
0.4×
Payout ratio
0.9×

Abbott Laboratories (ABT) news

The news and the share price important stories, numbered as below

Share price since 18 October +3.2%

Stories the last two months, newest first

  1. Commentary ·

    Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

    Abbott’s EP business grew at a mid-to-high-teens rate excluding LAA products in the third quarter of 2026, led by accelerating adoption of its Volt PFA catheter and international market-share gains. FDA approval of the TactiFlex Duo and planned U.S. launch, plus Volt’s expected Japan launch, could support further ablation growth. However, U.S. LAA orders are slowing as customers await the new Amulet 360, creating a headwind that management expects to persist through the fourth quarter. Abbott shares have fallen 16.5% over the past year, and its forward P/S multiple is above the industry average; the stock carries a Zacks Rank of Hold.

    Reported by Zacks

  2. 1 Results ·

    Abbott reports $13.01 billion in Q3 sales and narrows 2026 growth outlook

    Abbott reported Q3 2026 sales of $13.01 billion, up 14.5% year over year and slightly above estimates, while adjusted EPS rose 9.2% to $1.42 but missed consensus. Growth came across pharmaceuticals, medical devices, diagnostics and nutrition. Abbott narrowed its 2026 comparable sales growth outlook to about 6% from 6.5%-7.5%, while maintaining its adjusted EPS guidance midpoint.

    Reported by Zacks

  3. Commentary ·

    Abbott maintains 2026 EPS guidance as it plans nutrition spin-off

    Abbott’s reported third-quarter operating margin fell to 10.4% from 18.1% a year earlier, while adjusted margin rose to 23.4%. The company lowered its comparable 2026 sales-growth outlook to 6% but maintained adjusted EPS guidance of $5.50–$5.55. A planned nutrition-business spin-off by the end of 2027 is expected to raise the remaining company’s operating margin by about one percentage point, though separation costs will weigh on reported earnings.

    Reported by 2: Trefis · Simply Wall St.

  4. Product ·

    Abbott receives FDA and CE approval for UltiSynq defibrillation lead

    Abbott received FDA approval and CE Mark for UltiSynq, a defibrillation lead that supports both conduction system pacing and defibrillation. In the ASCEND CSP IDE trial, implantation succeeded in 98.5% of attempts, and defibrillation testing succeeded in all 120 patients tested. The lead also received FDA breakthrough device designation, expanding Abbott’s cardiac rhythm management portfolio.

    Reported by Zacks

  5. Commentary ·

    Analysts set Abbott’s average price target at $118.42

    Abbott shares have fallen 12.5% over the past year, underperforming the S&P 500 and healthcare sector. The company lowered its 2026 sales-growth forecast to about 6%, citing weaker heart-device sales and continued pressure on its nutrition business. Third-quarter adjusted EPS matched estimates at $1.42, while revenue slightly beat expectations at $13.01 billion. The average price target of $118.42 implies 7.2% upside.

    Reported by Barchart

  6. Product ·

    Abbott launches Panbio COVID-19 and flu self-test in Canada

    Abbott announced the Canadian availability of its Panbio COVID-19/Flu A&B home antigen test, which detects COVID-19 and influenza A and B from one nasal swab in about 15 minutes. Health Canada has authorized it for people aged two and older, and it is sold in single- and four-test kits at more than 1,800 pharmacies.

    Reported by CNW Group

  7. Commentary ·

    Abbott receives FDA approval for Amplatzer Paraclose PVL Occluder

    Abbott received FDA approval for its Amplatzer Paraclose PVL Occluder and reported encouraging study results for the investigational Amulet 360 occluder and SonicForce coronary IVL system, alongside the launch of its Oncodetect MRD test. The developments reinforce Abbott’s push into complex cardiology procedures and cancer monitoring, but are not expected to change its investment outlook materially yet.

    Reported by Simply Wall St.

  8. Other ·

    Abbott reports positive results for Amulet 360 and SonicForce trials

    Abbott reported positive one-year VERITAS results for its Amulet 360 left atrial appendage occluder and strong TECTONIC trial performance for its SonicForce coronary intravascular lithotripsy system. Amulet 360 achieved complete closure in 96.3% of patients, while SonicForce achieved 97% procedural success. Both results support Abbott’s cardiology device pipeline, but the products remain investigational in the U.S.

    Reported by 3: Benzinga · clinicaltrialsarena.com · Simply Wall St.

  9. Other ·

    Abbott begins pivotal trial of Cephea mitral valve system

    Abbott has begun a pivotal trial enrolling up to 585 patients in the U.S., Canada and Europe to evaluate its investigational Cephea mitral valve replacement system. The system is delivered through a leg vein, unlike Abbott’s Tendyne system, which requires a chest incision. The trial includes patients with moderate-to-severe mitral regurgitation or calcium-related mitral valve dysfunction.

    Reported by medtechdive.com

More headlines